Airway Epithelial Cell Differentiation for Authentic CF Models
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The lack of reliable sources of functional human proximal airway epithelial cells for mechanistic studies and drug discovery in cystic fibrosis research, as animal models do not accurately recapitulate the human condition, and existing therapies targeting CFTR mutations have shown poor clinical efficacy.
Innovation Solution
A method to differentiate induced pluripotent stem (iPS) cells into airway epithelial cells by culturing them in specific conditions to express markers like CCSP, KRT5, and FOXJ1, and proliferate without marker loss, using a three-dimensional scaffold to form engineered lung tissue.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If induced pluripotent stem cells are differentiated into airway epithelial cells using existing protocols, then alveolar type II cells can be generated, but the cells fail to express proximal airway markers (CCSP, KRT5, FOXJ1) and do not recapitulate human proximal airway pathology
Solution Approach 1:
The differentiation protocol is divided into distinct sequential stages: definitive endoderm formation, anterior foregut endoderm specification, and proximal airway epithelial cell differentiation. Each stage uses specific culture conditions and timeframes to guide cells through precise developmental transitions, ensuring expression of the correct marker profile for proximal airway cells rather than distal alveolar cells.
Solution Approach 2:
The protocol systematically changes cultural parameters including growth factor concentrations, medium composition, and oxygen tension at each differentiation stage. These parameter changes mimic in vivo developmental conditions and drive the cells toward proximal airway fate rather than distal alveolar fate, achieving reliable expression of CCSP, KRT5, and FOXJ1 markers.
2Reliability
If primary human proximal airway epithelial cells are obtained from tissue biopsies, then authentic cell markers are expressed, but the cells have limited proliferation capacity and are difficult to obtain
Solution Approach 1:
The protocol uses induced pluripotent stem cells as a preliminary source that can be expanded indefinitely before differentiation. This preliminary expansion step allows accumulation of sufficient cell numbers while maintaining the ability to differentiate into authentic proximal airway epithelial cells with proper marker expression, thus overcoming the limited proliferation of primary cells.
Solution Approach 2:
Instead of working directly with scarce primary cells, the protocol creates copies through iPS cell differentiation. The iPS cells serve as a renewable source that can be differentiated into multiple batches of authentic proximal airway epithelial cells, effectively copying the desired cell type without requiring repeated tissue biopsies.
3Adaptability or versatility
If animal models are used to study cystic fibrosis, then respiratory disease models are available, but the models do not accurately recapitulate human proximal airway epithelial cell pathology
Solution Approach 1:
The protocol creates human-specific cell copies through iPS cell differentiation, allowing study of human proximal airway pathology in vitro. This copying approach replaces animal models with human-derived cells that authentically express human markers and pathology, providing reliable human-specific disease modeling while maintaining the adaptability of in vitro experimental systems.
Data Source
Figure 1
Figure 2A~2D
Figure 3A
AI summary
The present invention provides compositions and methods of preparing airway cells. In one aspect, an epithelial airway cell derived from an induced pluripotent stem (iPS) cell characterized by expression of airway cell surface markers and an ability to proliferate is described. In another aspect, methods of differentiating an iPS into an epithelial airway cell is provided. Engineered lungs, methods of making such engineered lungs comprising the epithelial airway cells and treating respiratory disorders are also disclosed.